@ARTICLE{10.3389/fmed.2015.00037, AUTHOR={Brambilla, Tatiana and Fiamengo, Barbara and Tinterri, Corrado and Testori, Alberto and Grassi, Massimo Maria and Sciarra, Amedeo and Abbate, Tommaso and Gatzemeier, Wolfgang and Roncalli, Massimo and Di Tommaso, Luca}, TITLE={One-Step Nucleic Acid Amplification in Breast Cancer Sentinel Lymph Node: A Single Institutional Experience and a Short Review}, JOURNAL={Frontiers in Medicine}, VOLUME={2}, YEAR={2015}, URL={https://www.frontiersin.org/articles/10.3389/fmed.2015.00037}, DOI={10.3389/fmed.2015.00037}, ISSN={2296-858X}, ABSTRACT={Sentinel lymph node (SLN) examination is a standard in breast cancer patients, with several methods employed along its 20 years history, the last one represented by one-step nucleic acid amplification (OSNA). The latter is a intra-operative molecular assay searching for CK19 mRNA as a surrogate of metastatic cells. Our 3 years experience with OSNA (1122 patients) showed results overlapping those recorded in the same institution with a morphological evaluation (930 patients) of SLN. In detail, the data of OSNA were almost identical to those observed with standard post-operative procedure in terms of patients with positive SLN (30%) and micrometastatic/macrometastatic involvement of SLN (respectively, 38–45 and 62–55%). By contrast, when OSNA was compared to the standard intraoperatory procedure, it was superior in terms of accuracy, prompting the use of this molecular assay as a very valid, and reproducible for intra-operative evaluation of SLN. Further possibilities prompting the use of OSNA range from adhesion to quality control programs, saving of medical time, ability to predict, during surgery, additional nodal metastasis, and molecular bio-banking.} }